Greetings from Stanford Alpha Clinic!
We are a competency and resource hub for cell and gene therapy clinical trials at Stanford Medicine. Below is our best known list of Phase I, II, and III cell and gene therapy clinical trials that are currently enrolling or about to enroll participants at Stanford Medicine.
To learn more about a specific clinical trial, click on the NCT# to view the trial on clinicaltrials.gov. We plan to update this list and send regularly so that you are informed of Stanford Medicine’s latest offerings in cell and gene therapy.
Please use the contact us form if you would like to opt into receiving these quarterly updates via email. Feel free to reach out to us with any feedback or questions, as we strive to make cell and gene therapy clinical trials information accessible to all.
As you can see from the above banner, it takes a village for these trials to go from bench to bedside. We thank each and every faculty member, program, group, office, and team that helped contribute to this list.
The recruitment status of any given clinical trial is subject to change quickly. The list below is updated as of January 2026.
Adult Trials For:
NCT# |
Indication |
Title |
Investigator-Initiated or Industry-Sponsored? |
Investigator |
Age |
Contact |
Recurrent or Refractory B-Cell Lymphomas |
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Lymphomas
|
Stanford |
Matt Frank, MD, PhD |
18+ years |
Kendall Levine |
|
Relapsed or Refractory 2nd Line High-Risk Non Hodgkin’s Lymphoma |
Phase Ib Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL
|
Stanford |
Saurabh Dahiya, MD |
18+ years |
Kendall Levine
Sunny Salazar
|
|
Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma |
Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor |
Miltenyi Biosciences |
David Miklos, MD, PhD |
18+ years |
Christina Tran |
|
Relapsed and/or Refractory B-cell Lymphoma |
Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies |
Kite Pharma |
Saurabh Dahiya, MD |
18+ years |
Sunny Salazar
Shruti De
|
|
Relapsed and/or Refractory Multiple Myeloma |
A Phase I, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells |
Bristol-Myers Squibb |
Surbhi Sidana, MD |
18+ years |
Brent LaStofka |
|
Relapsed or Refractory AL Amyloidosis |
Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory (AL) Amyloidosis |
Nexcella Inc. |
Michaela Liedtke, MD |
18+ years |
Mani Gupta
|
|
Post stem cell transplant maintenance in Multiple Myeloma |
Phase 2 study to study the efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as post stem cell transplant maintenance in Multiple Myeloma (OPTIMMAL) |
Stanford |
Surbhi Sidana, MD |
18+ years |
Kimberly Truong Xie
Brent LaStofka |
|
Allogeneic Peripheral Blood Stem Cell Transplantation |
Phase III Trial of Tacrolimus/ Methotrexate/ Ruxolitinib versus Post-Transplant Cyclophosphamide/ Tacrolimus/ Mycophenolate Mofetil in NonMyeloablative/ Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation |
Clinical Trials Network (CTN) Project |
Vanessa Kennedy, MD |
18+ years |
Aliha H Mughal
|
|
Newly Diagnosed Chronic Graft-Versus-Host Disease |
A Phase 2 to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease |
Incyte |
Sally Arai, MD |
12+ years |
Melanie Gaudinez
|
|
Allogeneic Hematopoietic Cell Transplantation from an HLA-Mismatched Donor (7/8) |
ACCESS-T: Phase 1 Trial for Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation from an HLA-Mismatched Donor (7/8) with Orca-T |
Stanford |
Lori Muffly, MD |
18 to 70 years |
Alyssa Kanegai |
|
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation |
Phase II Randomized Trial Assessing Safety and Efficacy of Combination Reduced-dose Post-Transplant Cyclophosphamide, Tacrolimus, MMF, and Ruxolitinib as Graft-versus-Host Disease Prophylaxis in Adults with Hematologic Malignancies undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation |
National Marrow Donor Program (NMDP) Project |
Hany Elmariah, MD |
18 to 65 years |
Anna Cabot |
|
Aplastic Anemia |
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia |
Clinical Trials Network (CTN) Project |
Sally Arai, MD |
3 to 75 years |
Rinoa I. Ma
|
|
Advanced Hematologic Malignancies w/ T-Cell Depleted Graft |
Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft |
Stanford |
Everett Meyer, MD
|
18 to 75 years |
Lindsay Danley |
|
Hematologic Malignancies |
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults |
Stanford |
Alice Bertaina, MD, PhD |
1 month to 60 years |
||
Relapsed/Refractory Multiple Myeloma |
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
|
Stanford |
Lekha Mikkilineni, MD |
18+ years |
Natalie Chen |
|
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) |
A Phase 1 Study Evaluating BAFFR-targeting CAR T cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) |
Stanford |
Matt Frank, MD, PhD |
18+ years |
Priya Sharma priyas33@stanford.edu |
|
Hematologic Diseases |
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
|
Stanford |
Alice Bertaina, MD, PhD |
1 month to 45 years |
SCGT Clinical Trials Program |
Pediatric Trials For:
NCT# |
Indication |
Title |
Investigator-Initiated or Industry-Sponsored? |
Investigator |
Age |
Contact |
SIOD, FSGS, Cystinosis, SLE Nephritis, CKD Stage 4 |
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor |
Stanford |
Alice Bertaina, MD, PhD |
1 to 30 years |
SCGT Clinical Trials Program | |
Sickle Cell Disease |
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease (Restore) | Kamau Therapeutics, Inc. |
David Shyr, MD |
12 to 40 years |
||
Adenovirus, CMV, EBV post-transplant |
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity |
Stanford |
Jessie Alexander, MD |
1 month to 65 years |